1222998-36-8 | Torin 1

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$142.00	$99.00
10mg	≥95%	in stock	$188.00	$132.00
25mg	98%	in stock	$352.00	$247.00
50mg	≥95%	in stock	$691.00	$484.00

Description

• Catalog Number: AE35801
• Chemical Name: Torin 1
• CAS Number: 1222998-36-8
• Molecular Formula: C35H28F3N5O2
• Molecular Weight: 607.6243
• MDL Number: MFCD18782653
• SMILES: CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)n1c(=O)ccc2c1c1cc(ccc1nc2)c1cnc2c(c1)cccc2

Computed Properties

• Complexity: 1110
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 45
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 4
• XLogP3: 6

Literature

• Suppressed translation and ULK1 degradation as potential mechanisms of autophagy limitation under prolonged starvation.

  Autophagy 20160101

• EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.

  Molecular cell 20151015

• La-related Protein 1 (LARP1) Represses Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1 (mTORC1).

  The Journal of biological chemistry 20150626

• Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects.

  International journal of molecular sciences 20150101

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Found in translation of mTOR signaling.

  Cell research 20120901

• Generation of transgenic zebrafish with liver-specific expression of EGFP-Lc3: a new in vivo model for investigation of liver autophagy.

  Biochemical and biophysical research communications 20120601

• A unifying model for mTORC1-mediated regulation of mRNA translation.

  Nature 20120503

• Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.

  Molecular cancer research : MCR 20120501

• Current development of the second generation of mTOR inhibitors as anticancer agents.

  Chinese journal of cancer 20120101

• Development of ATP-competitive mTOR inhibitors.

  Methods in molecular biology (Clifton, N.J.) 20120101

• mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.

  Blood 20111222

• mTORC2 protein complex-mediated Akt (Protein Kinase B) Serine 473 Phosphorylation is not required for Akt1 activity in human platelets [corrected].

  The Journal of biological chemistry 20110715

• mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.

  American journal of physiology. Cell physiology 20110701

• Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability.

  Bioorganic & medicinal chemistry letters 20110701

• The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

  Science (New York, N.Y.) 20110610

• Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells.

  Blood 20110421

• Sindbis virus replication, is insensitive to rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells.

  Biochemical and biophysical research communications 20110311

• Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

  Journal of medicinal chemistry 20110310

• Dysregulation of epithelial Na+ absorption induced by inhibition of the kinases TORC1 and TORC2.

  British journal of pharmacology 20101201

• Lysosomal accumulation of mTOR is enhanced by rapamycin.

  Histochemistry and cell biology 20101201

• Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.

  Journal of medicinal chemistry 20101014

• An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

  The Journal of biological chemistry 20090320